Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Sandoz Launches Generic Claritin
July 26, 2012
- MTPC Launches Low-dose Anxiolytic Depas on July 24
July 26, 2012
- MSD Changes Name of Aroglycem to Diazoxide to Prevent Medication Errors
July 25, 2012
- MSD to File NDA for Odanacatib in Japan in First Half of 2013
July 25, 2012
- New Research Lab for Plasma Fractionation Business to Be Set Up in Kobe
July 25, 2012
- Nippon Kayaku to Increase Production of Carboplatin Due to Sandoz’s Shipment Suspension
July 25, 2012
- Meiji Seika Pharma Discontinues Development of Schizophrenia Treatment AM-831
July 24, 2012
- AnGes MG to Conduct Domestic PI/II Trials of Collategene for Lymphedema in Fall
July 24, 2012
- IBL-Japan Concludes Codevelopment Agreement with IBL International for Diagnostic for Alzheimer Disease
July 24, 2012
- Kyowa Kirin Revises Business Forecast Upward on Steady Sales of Nesp
July 24, 2012
- Confident of Posting Sales of 100 Billion Yen with 3 Focal Products Including Teribone: Asahi Kasei Pharma President Asano
July 24, 2012
- Combination Drug Containing JR-051 to Be Developed: JCR
July 23, 2012
- Azilva Ranked No. 1 in Both HP, GP Markets for 2 Straight Months: Rep Track Survey
July 23, 2012
- Patent Cliff for Kipres Looms; Will Kyorin Continue to Stand Alone in Respiratory Disease Field?
July 23, 2012
- HBM Taking Advantage of Avian Biotechnology for Antibody Drug Discovery: President Toyoura
July 23, 2012
- Aricept Successor BACE Inhibitor Reduced Aβ in PI Studies: Eisai
July 20, 2012
- Inlyta as Standard Drug in Second-Line Treatment: Pfizer
July 20, 2012
- Sandoz Initiates Voluntary Recall of Carboplatin, Shipment Suspended
July 20, 2012
- Otsuka Starts PIII Trial of Rebamipide Ophthalmic Suspension in US
July 20, 2012
- Alfresa HD to Make Tokiwa Yakuhin Wholly-Owned Subsidiary
July 19, 2012
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…